CONCORDBIO Concord Biotech Q2 FY26 results (Jul–Sep 2025) and concall
Concord Biotech reported a subdued Q2 FY26 primarily due to temporary timing issues, including a delay in CDSCO written confirmations for EU exports and the deferment of a Middle East government tender. Despite the YoY revenue dip, underlying unit economics remain strong with adjusted EBITDA margins at 41%. Management expressed high confidence in a stronger H2 FY26 as deferred shipments resume and the new injectable facility at Valthera begins to scale.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 20.3%, net profit down 36.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 310 | 244 | 430 | 204 | 247 −20% |
| EBITDA | 137 | 98 | 190 | 61 | 91 −34% |
| Net profit | 99 | 74 | 142 | 43 | 63 −36% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
